Chris Allen, CEO of UK-based analytical testing and scientific consultancy provider Broughton, explains the challenges — and opportunities — that Brexit holds for laboratory services.
Mark Arnold, MD of ONFAB, part of Envair Technology, describes the challenges in handling HPAPIs and how pharma manufacturers can learn to manage the risk involved.
Melissa Mooney, director of eCOA Solutions Engineering at IQVIA, explains how successful oncology drug development relies on an accurate depiction of the patient voice, as well as 5 key considerations for developing a patient-centric eCOA strategy.
Michael Earl, director, Pharmaceutical Services at Owen Mumford, explains how Owen Mumford’s Covid-compliant study design and careful planning allowed them to finalise their product design and present this innovative product to the market.
Mark Gregory, chief pharmacy officer for Pleio, focuses on pharmacy services as a component of healthcare delivery, and the power of the human connection in optimising pharmacy’s digital transformation.
Mark Tunkel, global category director, Services at Nemera, explores the factors that should be considered when developing a device strategy in the current technology landscape, and how a holistic approach can lead to better decisions.
Anne-Cecile Bayne, global science & innovation lead Pharma & Medical Nutrition, DSM discusses the benefits of using antioxidants to block nitrosamine development in drug products, and futureproof pharma formulations.
Datwyler Healthcare's Tabassam Sharif, regulatory affairs manager and Eugene Polini, technical key account manager, explain how parenteral packaging suppliers are optimising their technologies and processes to meet regulatory requirements.
Sally-Anne Whybrow, healthcare business development manager, Siemens Financial Services, UK examines how smart financing can help CROs invest in financially-sustainable technology.
Rebekah Jordan shares her view from the seat at the Editor’s Desk on what impact the post-Brexit era might have on the UK process of medicine approvals and how external pharma manufacturers may respond.
Henk de Wilde, chief operating officer and R&D Director, iQure Pharma discusses how better understanding of pain is helping researchers to develop novel therapeutics as non-opioid alternatives to manage neuropathic pain.
EPM spoke exclusively with Heiko Schmidt, Strategy & Consulting Life Sciences lead, Accenture AG, about why CDMOs should be prepared to track sustainability metrics now and how companies which wait, will likely be forced to catch-up at higher costs.
